Venus Remedies reports positive result in Phase-3 Clinical Trials for ELORES

16 Nov 2018 Evaluate

Venus Remedies has reported positive Top-Line results in its Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific meeting of the Infectious Diseases Society of America (IDSA).

The company's four abstracts were accepted for poster presentations at the IDWeek 2018. These posters covered the efficacy results from the plea clinical trial, as well as supportive in vitro efficacy data from an AMR Surveillance study.

Venus Remedies is a pharmaceutical manufacturing company. The company is engaged in manufacturing products catering to various segments such as Oncology, Cephalosporins, Carbapenems and Other Specialties.

Venus Remedies Share Price

738.90 -22.60 (-2.97%)
06-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1694.70
Dr. Reddys Lab 1241.15
Cipla 1330.80
Zydus Lifesciences 887.85
Lupin 2168.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×